Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CHAMBERS MEDICAL GROUP, PLLC

NPI: 1982052114 · LAS VEGAS, NV 89130 · Multi-Specialty Clinic/Center · NPI assigned 05/27/2016

$9.92M
Total Medicaid Paid
190,532
Total Claims
168,449
Beneficiaries
19
Codes Billed
2018-01
First Month
2024-11
Last Month

Provider Details

Authorized OfficialCHAMBERS, ZACHARIAH (MD)
NPI Enumeration Date05/27/2016

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 9,763 $496K
2019 34,390 $2.59M
2020 32,969 $1.69M
2021 35,388 $1.61M
2022 32,412 $1.42M
2023 29,162 $1.28M
2024 16,448 $839K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 70,997 62,969 $4.37M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 78,166 67,682 $2.17M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 9,366 7,923 $1.26M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 16,678 15,786 $893K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 6,040 5,751 $296K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 2,429 2,244 $271K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 2,120 1,982 $258K
64483 1,461 1,232 $145K
64635 454 383 $82K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 725 682 $60K
64493 410 363 $40K
64494 410 365 $22K
64636 448 364 $21K
64484 279 217 $9K
72275 284 264 $7K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 71 71 $7K
64479 58 42 $6K
62323 80 79 $6K
20611 56 50 $3K